March 20, 2025

ExoMira receives an outstanding fundable score on a highly competitive SBIR grant, positioning the company for future scale-up toward clinical trials.

March 10, 2025

ExoMira appoints Yan He as Director of Business & Clinical Development, strengthening its business development, clinical, and regulatory leadership as ExoMira advances toward first-in-human studies.

January 15, 2025

ExoMira appoints Dr. Alex Le as Executive Advisor and Board Member, bolstering the company’s strategic growth, commercialization planning, and industry connectivity as it scales its pancancer immunotherapy platform.

January 5, 2025

ExoMira joins NIH-funded Multi-PI R01 grant led by co-founders Drs. Fang and Liu to develop dual-efficacy therapies for breast cancer.

November 13, 2024

Dr. Huiping Liu presented research on CTC cluster plasticity at EACR Liquid Biopsies 2024, reinforcing ExoMira’s scientific foundation in metastasis biology.

June 15, 2024

Dr. Huiping Liu has been named a Chan Zuckerberg Biohub Chicago Investigator, receiving multiyear funding to support innovative cancer research aligned with ExoMira’s mission.